CLINICAL NONSECRETINGPITUATARY MACROADENOMA MANAGED BYCABERGOLINE: ANYBODY, ANYTIME?

Arhire Amalia Ioana¹, Luminita Cima¹², Iuliana Pascu¹, Simona Fica¹², Carmen Gabriela Barbu¹²,

¹ Endocrinology, Diabetes and Metabolic Diseases Department, Elias Hospital, Bucharest, Romania ² "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania

Pathologic antecedents:

- •Pituitary macrodenoma(37/45/47mm) with compressive syndrome left cecity (June 2014)
- •Partial ablation of the adenoma (July 2014)- with IHC prolactin, LH, FSH, TSH and GH staining
- •Iatrogenic partial pituitary insufficiency ACTH, TSH (substituted) (July 2014)

M. G., 16 years and 3 months old male



• short stature (-3.5 SD) in the context of the iatrogenic pituitary insufficiency

Clinically:

- -short stature (149.9cm, -3.5 DS)
- -underweight (BMI=17.57 kg/m2 -5th percentile
- =18.6 kg/m2
- -BP=95/60 mmHg(orthostatic and clinostatic)
- -Tanner stage P3G3
- -left temporal hemianopsia

Biologically:

Hormone	Value	Normal value
TSH	0.700 mIU/ml	(0.34-6.1)
fT4	0.977 ng/dl	(0.89-1.76)
Testosterone	335 ng/dl	(223-1108)
IGF1	56.9 ng/ml	(136-285)
ACTH	12.1 pg/ml	(7.2-63.3)
Cortizol (8AM)	22.6 ug/dl	(5-25)
GH (base)	0.191 ng/ml	
GH (maximum value in Insulin Induced Hypoglicemia)	0.179 ng/ml	(>10)
iPTH	13.2 pg/ml	(15-65)
PRL	292uUI/ml(<320)	


Pituitary MRI: adenoma of 3.2/3.56/3.4 cm, which invades the sphenoid sinus, the right cavernous sinus, it has contact with the right internal carotid artery and pushes the left internal carotid and also with the distal segment of the optic nerves Hand X-ray: a bone age of 16 years

Visual field: left temporal hemianopsy

Díagnostíc

Non secreting pituitary macoadenoma with compressive syndrome Partial pituitary insufficiency - TSH, ACTH, GH Short stature due to the GH dephiciency Left temporal hemianopsia





Pituitary MRI


Treatment: -indication for surgery

BUT – Refuse of family

-Cabergoline - started with a dose of 1 mg/week and progressively increased the dosage up to 3 mg/week, with visual field evaluation every 1-2 months and MRI after 6 months

After 6 months:

-clinically: nausea and weight loss (1 kg in the last month)
-visual field: bilateral hemianopsia
-stationary MRI



Surgery



Conclusion: Cabergoline treatment of nonsecreting tumors with IHC staining for D2 receptors is a new strategy with optimist results in recent studies; however, close monitoring is mandatory during the treatment in order to identify non responders and assure an individualized therapeutic decision.

